PlexBio Co., Ltd. (TPEX:6572)

Market Cap	694.45M -41.2%
Revenue (ttm)	153.06M +47.7%
Net Income	-64.51M
EPS	-0.62
Shares Out	103.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	232,593
Average Volume	174,191
Open	6.57
Previous Close	6.81
Day's Range	6.46 - 6.79
52-Week Range	6.39 - 12.70
Beta	0.18
RSI	35.96
Earnings Date	Apr 27, 2026

About PlexBio

PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for πCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and πCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6572

Financial Performance

In 2024, PlexBio's revenue was 128.06 million, a decrease of -23.40% compared to the previous year's 167.18 million. Losses were -61.63 million, 5.30% more than in 2023.